Forest Laboratories, LLC Form 4 July 03, 2014

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL OMB** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

| 1. Name and Address of Reporting Person * LIEBERMAN GERALD M |                     |           | 2. Issuer l<br>Symbol          | Name <b>and</b> T | Ficker or Trading       | 5. Relationship of Reporting Person(s) to Issuer        |                  |             |  |
|--|---------------------|-----------|--------------------------------|-------------------|-------------------------|---|------------------|-------------|--|
|  |                     |           | Forest La                      | boratorie         | s, LLC [FRX]            | (Check all applicable)                                  |                  |             |  |
| (Last)   | (First) (Mi         | ddle)     | 3. Date of I                   |                   |                         |   |                  |             |  |
|  |                     |           | (Month/Da                      | y/Year)           |                         | _X_ Director  | 10%              | 6 Owner     |  |
| C/O FOREST LABORATORIES,                                     |                     |           | 07/01/20                       | 14                |                         |   | e titleOth       | er (specify |  |
| INC., 909 TH   | HIRD AVENUE         | ŕ         |                                |                   |                         | below)  | below)           |             |  |
| (Street)   |                     |           | 4. If Amendment, Date Original |                   |                         | 6. Individual or Joint/Group Filing(Check               |                  |             |  |
|  |                     |           | Filed(Month/Day/Year)          |                   |                         | Applicable Line) _X_ Form filed by One Reporting Person |                  |             |  |
| NEW YORK   | x, NY 10022         |           |                                |                   |                         | Form filed by l<br>Person                               | More than One Re | eporting    |  |
| (City)   | (State) (Z          | Cip)      | Table                          | I - Non-De        | rivative Securities Acc | quired, Disposed o                                      | f, or Beneficial | lly Owned   |  |
| 1.Title of   | 2. Transaction Date | 2A. Dee   | emed                           | 3.                | 4. Securities           | 5. Amount of  | 6. Ownership     | 7. Nature   |  |
| Security   | (Month/Day/Year)    | Execution | on Date, if                    | Transactio        | onAcquired (A) or       | Securities  | Form: Direct     | Indirect    |  |
| (Instr. 3)   |                     | any       |                                | Code              | Disposed of (D)         | Beneficially  | (D) or           | Beneficia   |  |
|  |                     | /3 F .1 / | T 13.7                         | (T . O)           | (T . O . 1 . T)         | 0 1   | T 1' (T)         | 0 1 .       |  |

| 1.Title of          | 2. Transaction Date | 2A. Deemed         | 3.                         | 4. Securi           | ties      |            | 5. Amount of     | 6. Ownership | 7. Nature of |
|---------------------|---------------------|--------------------|----------------------------|---------------------|-----------|------------|------------------|--------------|--------------|
| Security            | (Month/Day/Year)    | Execution Date, if | TransactionAcquired (A) or |                     |           |            | Securities       | Form: Direct | Indirect     |
| (Instr. 3)          |                     | any                | Code                       | Disposed of (D)     |           |            | Beneficially     | (D) or       | Beneficial   |
|                     |                     | (Month/Day/Year)   | (Instr. 8)                 | (Instr. 3, 4 and 5) |           | Owned      | Indirect (I)     | Ownership    |              |
|                     |                     |                    |                            |                     |           |            | Following        | (Instr. 4)   | (Instr. 4)   |
|                     |                     |                    |                            |                     | (4)       |            | Reported         |              |              |
|                     |                     |                    |                            |                     | (A)       |            | Transaction(s)   |              |              |
|                     |                     |                    | Code V                     | Amount              | or<br>(D) | Price      | (Instr. 3 and 4) |              |              |
| Common<br>Stock     | 07/01/2014          |                    | D                          | 1,527               | D         | <u>(1)</u> | 0                | D            |              |
| Restricted<br>Stock | 07/01/2014          |                    | D                          | 2,406               | D         | <u>(2)</u> | 0                | D            |              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Forest Laboratories, LLC - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | ransactiorDerivative<br>Code Securities |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     |
|---|---|---|---|--|---|--------|--|--------------------|---|-------------------------------------|
|   |   |   |   | Code V                                 | (A)                                     | (D)    | Date<br>Exercisable                                      | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 33.43  | 07/01/2014                              |   | D                                      |   | 20,000 | (3)  | 08/22/2021         | Common<br>Stock   | 20,000                              |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 34.54  | 07/01/2014                              |   | D                                      |   | 7,815  | <u>(5)</u>   | 08/22/2022         | Common<br>Stock   | 7,815                               |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 42.61  | 07/01/2014                              |   | D                                      |   | 5,909  | <u>(6)</u>   | 08/14/2023         | Common<br>Stock   | 5,909                               |

## **Reporting Owners**

| Reporting Owner Name / Address | Kelationships |           |         |       |  |  |
|--------------------------------|---------------|-----------|---------|-------|--|--|
|                                | Director      | 10% Owner | Officer | Other |  |  |

LIEBERMAN GERALD M C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022

X

### **Signatures**

/s/ Rita Weinberger as attorney-in-fact for Gerald M.
Lieberman 07/02/2014

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of common stock was disposed of pursuant to the Merger Agreement, dated as of February 17, 2014 (the "Merger Agreement"), by and among the issuer and Actavis plc ("Actavis"), Tango US Holdings Inc., Tango Merger Sub 1 LLC, and Tango Merger Sub 2 LLC in exchange for either (A) \$26.04 in cash plus 0.3306 Actavis ordinary shares having a market value of \$224 per share on the effective date of the merger or (B) \$25.67 in cash plus 0.332623 Actavis ordinary shares having a market value of \$224 per share

Reporting Owners 2

#### Edgar Filing: Forest Laboratories, LLC - Form 4

on the effective date of the merger, depending on the consideration election made by the reporting person and the consideration election proration procedures set forth in the Merger Agreement.

- (2) Pursuant to the terms of the Merger Agreement, each restricted share of common stock converted as of the effective time of the transaction into the right to receive \$103.43 in cash.
- (3) The options include 15,000 that are currently exercisable and 5,000 that vest on August 23, 2014.
  - Pursuant to the terms of the Merger Agreement, (a) each vested option to purchase issuer common stock was assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such vested option multiplied by (ii) 0.4723, at an exercise price per
- (4) share equal to the quotient obtained by dividing (x) the exercise price per share of such vested option by (y) 0.4723; and (b) each unvested option to purchase common stock converted as of the effective time of the transaction into the right to receive an amount in cash equal to the product of the excess, if any, of \$103.43 over the exercise price per share of such unvested option multiplied by the number of shares of issuer common stock subject to such option.
- (5) The options are currently exercisable.
- (6) The options are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.